Medicus Pharma announcs its INAD received MUMS from U.S. FDA

Medicus Pharma (MDCX) announces that its Investigational New Animal Drug, INAD, has received Minor Use in Major Species Designation, MUMS, from the U.S. Food and Drug Administration, FDA, for its dissolvable Doxorubin-containing microneedle array, D-MNA, to treat external squamous cell carcinoma, SCC, in horses. The company received a notification from the FDA on December 9th 2024.